CENTOGENE is a rare disease company focused on transforming clinical, genetic, and biochemical data into medical solutions for Patients. With headquarters in Rostock, Germany and further operations in Berlin, Germany as well as Cambridge, Massachusetts, USA, CENTOGENE is dedicated to transforming the science of genetic information into solutions and hope for patients with rare diseases and their families.

CENTOGENE provides the full spectrum of modern methods and technology for human genetics analysis; it is active in research and is constantly developing new and innovative products for human genetics.

We are committed to ‘un-rare’ rare diseases by using our worldwide knowledge in the rare disease market, understanding the epidemiology, analyzing clinical heterogeneity of the more than 3800 diseases and developing innovative biomarkers. Based on this knowledge we are bringing rationality to treatment decisions and, thereby, accelerate the development of new orphan drugs.

We are accelerating the development of orphan drugs

We are a globally active IT based, knowledge generating biotechnology company in orphan diseases

We are committed to ’unrare’ rare diseases by using our worldwide knowledge in the rare disease market

We have developed a multiomic- technology platform combining genomics, proteomics and metabolomics

CENTOGENE was founded in 2006 on the vision of the Company’s founder Dr. Arndt Rolfs, a Neurologist with vast clinical experience in rare hereditary diseases: transform the science of clinical and genetic data into medical solutions for patients with orphan diseases.

This vision is based on the fact that among the 7,000 identified rare diseases, it is estimated that 80% – or 5,600 – have a genetic origin. Of these hereditary rare diseases, roughly only 4 % have an FDA approved treatment.

As it normally takes an average of around seven years for a patient with a rare disease to be diagnosed, there is a significant unmet global need for high-quality genetic information in the rare disease space for the early identification, effective treatment of patients, and the acceleration of orphan drug development.

CENTOGENE’s data repository, which we believe the world’s largest repository for genetic information on rare hereditary diseases in the world, is the foundation of CENTOGENE’s pursuit of Dr. Rolfs’ vision. The data repository combines worldwide clinical and epidemiological data, and detailed access to phenotype, genotype, proteomics, and metabolomics data to aid in the development of new treatments. 

CENTOGENE is guided on the belief that a detailed, global understanding of the genetic basis and the clinical phenotype of rare hereditary diseases will unlock the ability to target rare diseases, and provide critical knowledge that will guide and facilitate every stage of ophan drug development.

CENTOGENE focuses on changing the way patients with rare diseases are diagnosed and treated

Laboratories, sales and administrative offices located in Rostock, Berlin, Boston, Vienna, Dubai and Delhi

Over 400 highly qualified international personnel active in genetics, bioinformatics, IT, proteomics and metabolomics